SCHIZOPHRENIA RESEARCH

THE OFFICIAL JOURNAL OF THE SCHIZOPHRENIA INTERNATIONAL RESEARCH SOCIETY

Vol. 85, Nos. 1–3 **July 2006**

CONTENTS

Cited in: *Current Contents/Life Sciences, Current Contents/Clinical Medicine, EMBASE/Excerpta Medica, Psychological Abstracts, PsychINFO, PsychALERT, Index Medicus*

Special section on Cognition, guest-edited by P.D. Harvey

Evidence for impaired mnemonic strategy use among patients with schizophrenia using the part-list cuing paradigm
B.K. Christensen, T.A. Girard, A.S. Benjamin and P. Vidailhet 1

Three dimensions of clinical symptoms in elderly patients with schizophrenia: Prediction of six-year cognitive and functional status
E. Chemerinski, A. Reichenberg, B. Kirkpatrick, C.R. Bowie and P.D. Harvey 12

A comparison of cognitive structure in schizophrenia patients and healthy controls using confirmatory factor analysis
D. Dickinson, J.D. Ragland, M.E. Calkins, J.M. Gold and R.C. Gur 20

Cognitive deficits and levels of IQ in adolescent onset schizophrenia and other psychotic disorders
B. Fagerlund, A.K. Pagsberg and R.P. Hemmingsen 30

Associating functional recovery with neurocognitive profiles identified using partially ordered classification models
J. Jaeger, C. Tatsuoka, S. Berns, F. Varadi, P. Czobor and S. Uzelac 40

Premorbid intra-individual variability in intellectual performance and risk for schizophrenia: A population-based study
A. Reichenberg, M. Weiser, M.A. Rapp, J. Rabinowitz, A. Caspi, J. Schmeidler, H.Y. Knobler, G. Lubin, D. Nahon, P.D. Harvey and M. Davidson 49

Altered brain activation in dorsolateral prefrontal cortex in adolescents and young adults at genetic risk for schizophrenia: An fMRI study of working memory
L.J. Seidman, H.W. Thermenos, R.A. Poldrack, N.K. Peace, J.K. Koch, S.V. Faraone and M.T. Tsuang 58

Cognitive effects of adjunctive 24-weeks Rivastigmine treatment to antipsychotics in schizophrenia: A randomized, placebo-controlled, double-blind investigation
T. Sharma, C. Reed, I. Aasen and V. Kumari 73

Neurocognitive and social cognitive correlates of formal thought disorder in schizophrenia patients
K.L. Subotnik, K.H. Nuechterlein, M.F. Green, W.P. Horan, T.M. Nienow, J. Ventura and A.T. Nguyen 84

Facial emotion recognition from moving and static point-light images in schizophrenia
E.K. Tomlinson, C.A. Jones, R.A. Johnston, A. Meaden and B. Wink 96

Optimization of a multinomial model for investigating hallucinations and delusions with source monitoring
T.S. Woodward, M. Menon, X. Hu and R.S.E. Keefe 106

Research papers

Decision-making impairments in adolescents with early-onset schizophrenia
H.M. Kester, S. Sevy, E. Yechiam, K.E. Burdick, K.L. Cervellione and S. Kumra 113

Comorbid diagnoses in patients meeting criteria for the schizophrenia prodrome
J.L. Rosen, T.J. Miller, J.T. D'Andrea, T.H. McGlashan and S.W. Woods 124

Neuropsychological functioning and social anhedonia: Results from a community high-risk study
A.S. Cohen, W.W. Leung, A.M. Saperstein and J.J. Blanchard 132

Facial affect recognition: A mediator between cognitive and social functioning in psychosis?
J. Addington, H. Saeedi and D. Addington 142

Impaired error monitoring contributes to face recognition deficit in schizophrenia patients
H. Silver, C. Goodman, W. Bilker, R.C. Gur, V. Isakov, G. Knoll and P. Feldman 151

Do people with a first episode of psychosis differ in personality profiles?
M.-C. Beauchamp, T. Lecomte, C. Lecomte, C. Leclerc and M. Corbière 162

Are deficits in executive sub-processes simply reflecting more general cognitive decline in schizophrenia?
G. Donohoe, S. Clarke, D. Morris, J.-M. Nangle, S. Schwaiger, M. Gill, A. Corvin and I.H. Robertson 168

(Contents continued on last page of this issue)

0920-9964(200607)85:1-3;1-3

(contents continued from outside backcover)

The speed of visual attention in schizophrenia: Electrophysiological and behavioral evidence
S.J. Luck, R.L. Fuller, E.L. Braun, B. Robinson, A. Summerfelt and J.M. Gold 174
Neurocognition and suicidal behaviour in an Irish population with major psychotic disorders
J.-M. Nangle, S. Clarke, D.W. Morris, S. Schwaiger, K.A. McGhee, N. Kenny, K. Murphy, M. Gill, A. Corvin and G. Donohoe 196
Deficits in memory strategy use are related to verbal memory impairments in adolescents with schizophrenia-spectrum disorders
D. Roofeh, J. Cottone, K.E. Burdick, T. Lencz, K. Gyato, K.L. Cervellione, B. Napolitano, H. Kester, B. Anderson and S. Kumra 201
Neuropsychological deficits in nonsmokers with schizophrenia: Effects of a nicotinic antagonist
K.A. Sacco, A. Termine, M.M. Dudas, A.A. Seyal, T.M. Allen, J.C. Vessicchio, B.E. Wexler and T.P. George 213
Impact of haloperidol, a dopamine D_2 antagonist, on cognition and mood
H. Saeedi, G. Remington and B.K. Christensen 222
D2/D3 dopamine receptor binding with [F-18]fallypride in thalamus and cortex of patients with schizophrenia
M.S. Buchsbaum, B.T. Christian, D.S. Lehrer, T.K. Narayanan, B. Shi, J. Mantil, E. Kemether, T.R. Oakes and J. Mukherjee 232
Schizophrenia-associated reduction of neuronal and oligodendrocyte numbers in the anterior principal thalamic nucleus
W. Byne, S. Kidkardnee, A. Tatusov, G. Yiannoulos, M.S. Buchsbaum and V. Haroutunian 245
A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization
S.G. Potkin, G.M. Gharabawi, A.J. Greenspan, R. Mahmoud, C. Kosik-Gonzalez, M.F.T. Rupnow, C.A. Bossie, M. Davidson, V. Burtea, Y. Zhu and J.K. Trivedi 254
Hearing impairment and psychosis: A replication in a cohort of young adults
N. Stefanis, V. Thewissen, C. Bakoula, J. van Os and I. Myin-Germeys 266
The five-factor model of the Positive and Negative Syndrome Scale I: Confirmatory factor analysis fails to confirm 25 published five-factor solutions
M. van der Gaag, A. Cuijpers, T. Hoffman, M. Remijsen, R. Hijman, L. de Haan, B. van Meijel, P.N. van Harten, L. Valmaggia, M. de Hert and D. Wiersma 273
The five-factor model of the Positive and Negative Syndrome Scale II: A ten-fold cross-validation of a revised model
M. van der Gaag, T. Hoffman, M. Remijsen, R. Hijman, L. de Haan, B. van Meijel, P.N. van Harten, L. Valmaggia, M. de Hert, A. Cuijpers and D. Wiersma 280
A validation of a new measure of activity in psychosis
S. Jolley, P.A. Garety, L. Ellett, E. Kuipers, D. Freeman, P.E. Bebbington, D.G. Fowler and G. Dunn 288

Letter to the Editors

Usefulness of glycosylated haemoglobin (HbA1c) to screen for diabetes in patients with schizophrenia
L. Hanssens, M. De Hert, D. Van Eyck, M. Wampers, A. Scheen and J. Peuskens 296
Aripiprazole and the Neuroleptic Malignant Syndrome
J.R. Strawn 298
Accelerometry is a valid measure of physical inactivity but not of energy expended on physical activity in people with schizophrenia
J.-K. Sharpe, T.J. Stedman, N.M. Byrne and A.P. Hills 300
Galantamine added to antipsychotic treatment in chronic schizophrenia: Cognitive improvement?
U. Norén, A. Björner, O. Sonesson and L. Eriksson 302

Erratum

Erratum to "Manual for the Extrapyramidal Symptom Rating Scale (ESRS)" [Schizophrenia Research 76 (2–3) (2005) 247–265]
G. Chouinard and H.C. Margolese 305